Supreme Court divided over whether federal law blocks Roundup cancer lawsuits
A ruling for Bayer could extinguish a multibillion-dollar wave of state-court litigation over glyphosate.
Briefing
- •The Supreme Court heard oral arguments on whether federal pesticide approval law pre-empts state-court claims that Roundup causes cancer, with justices appearing divided.
- •The case carries multibillion-dollar stakes for Bayer, which acquired Roundup maker Monsanto and has faced thousands of lawsuits alleging glyphosate causes non-Hodgkin lymphoma.
- •A ruling in Bayer's favour would effectively block the bulk of remaining litigation by establishing federal regulatory approval as a shield against state tort claims.
- •The court's apparent division signals no clear majority for either full pre-emption or full liability exposure, leaving the outcome uncertain.
- •The case has drawn political attention from the MAHA movement, whose supporters oppose pesticide use and have warned of midterm consequences if the court sides with Bayer.
Analysis
- →A divided court ruling rather than a clean Bayer win leaves the litigation liability pool intact. Bayer faces continued reserve requirements and settlement pressure across thousands of remaining glyphosate cases, constraining BAYRY's ability to deploy capital toward dividends, buybacks, or the pipeline investments needed to offset its agricultural revenue plateau. A narrow or fractured ruling that falls short of full preemption may also invite further state-level tort activism against other agrochemical companies with EPA-approved products.
- →The MAHA movement's explicit political threat over a pro-Bayer ruling creates a rare dynamic where the administration faces electoral pressure not to file an amicus brief supporting preemption, and where any ruling perceived as corporate-friendly on pesticide safety could amplify anti-agrochemical regulatory momentum under RFK Jr.'s HHS influence. Other agrochemical companies with pending EPA registrations, including CORTEVA and FMC, should treat this as a signal that federal regulatory approval may provide diminishing litigation shelter regardless of the court's technical holding.
Historical Context
- 2018-2019
Bayer completed the $63 billion Monsanto acquisition in 2018 and within months faced the first Roundup trial loss. The acquired litigation liability wiped out a significant portion of the deal's strategic rationale and triggered years of reserve-building, demonstrating how M&A-inherited tort exposure can persistently suppress acquirer returns on equity.
- 2000s
In Riegel v. Medtronic (2008) the Supreme Court held that FDA pre-market approval preempts state tort claims for medical devices, providing a preemption template that Bayer's legal team has drawn on. The distinction the current Court is wrestling with is whether EPA pesticide registration carries equivalent preemptive force, since the statutory language differs from the medical device statute.
